We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02183805
Recruitment Status : Terminated (Difficulty accruing subjects the study accrual was closed)
First Posted : July 8, 2014
Last Update Posted : July 23, 2021
Information provided by (Responsible Party):
Zhong-yu Yuan, Sun Yat-sen University

Brief Summary:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

Condition or disease Intervention/treatment Phase
Carcinoma Breast Stage IV Drug: Abraxane,Cyclophosphamide,Carboplatin Phase 2

Detailed Description:
To explore the progression-free survival of patients with metastatic triple-negative breast cancer treated with peripheral blood stem cell transplant (PBSCT) followed by high dose chemotherapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therapy for Metastatic Triple-negative Breast Cancer
Actual Study Start Date : June 17, 2014
Actual Primary Completion Date : December 15, 2020
Actual Study Completion Date : December 15, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Metastatic triple negative breast cancer
Drug: Abraxane,Cyclophosphamide,Carboplatin
High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
Other Names:
  • Abraxane 800 mg/m2
  • Cyclophosphamide 3g/m2
  • Carboplatin 800 mg/m2

Primary Outcome Measures :
  1. Progression free Survival [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) 0 or 1.
  • Histologically or cytologically proven diagnosis of breast cancer with evidence of locally recurrent or metastatic disease.
  • Documentation of estrogen and progestin receptor (ER/PR) negative status and HER2/neu receptor negative status (ie, FISH negative or immunohistochemistry 0 or +1).
  • Obtained complete response or Good partial response after first line chemotherapy.
  • Normal organ function required prior to study entry.
  • Willingness to comply with treatment plans and other study procedures.

Exclusion Criteria:

  • Uncontrolled central nervous system (CNS) involvement with disease
  • Fertile women unwilling to use contraceptive techniques during treatment
  • Females who are pregnant
  • Organ dysfunction.
  • Patients may not be receiving any other investigational agents.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02183805

Layout table for location information
China, Guangdong
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Sponsors and Collaborators
Sun Yat-sen University
Layout table for investigator information
Principal Investigator: Zhong-Yu Yuan, M.D. Sun Yat-sen University
Layout table for additonal information
Responsible Party: Zhong-yu Yuan, Sun Yat-sen University Cancer Center, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT02183805    
Other Study ID Numbers: SYSUCC-004
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 23, 2021
Last Verified: July 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Zhong-yu Yuan, Sun Yat-sen University:
triple negative breast cancer
autologous hematopoietic stem-cell transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators